Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
Author:
Funder
Bristol-Myers Squibb
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/25/11/2277/326773/mdu441.pdf
Reference23 articles.
1. Systematic review of medical treatment in melanoma: current status and future prospects;Garbe;Oncologist,2011
2. Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma;Maio,2013
3. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials;Wolchok;Ann Oncol,2013
4. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy;Hoos;Semin Oncol,2010
5. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma;Wolchok;Ann NY Acad Sci,2013
Cited by 118 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC);Cancers;2023-07-10
2. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma;European Journal of Cancer;2023-06
3. The role of mitochondria in the resistance of melanoma to PD-1 inhibitors;Journal of Translational Medicine;2023-05-23
4. Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?;Pharmaceutics;2023-03-02
5. Nanomedicines in cancer immunotherapy: challenges and opportunities;Nanotechnology and Human Health;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3